Search

Displaying results 2351 - 2360 of 2821 in total
  1. Drug

    WIN 55212-2

    go.drugbank.com/drugs/DB13950
    Experimental

    WIN 55,212-2 is a chemical described as an aminoalkylindole derivative, which produces effects similar to those of cannabinoids such as tetrahydrocannabinol (THC) but has an entirely different chemical structure. It is a potent cannabino...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  2. Drug

    1,2-dichlorobenzene

    go.drugbank.com/drugs/DB13963
    ApprovedWithdrawn

    1,2-Dichlorobenzene, also named ortho-dichlorobenzene, is an organic compound. It is a non-polar colorless liquid that is miscible in most organic solvents. This derivative of benzene differs from the parent compound by the presence of t...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  3. Drug

    Nomegestrol acetate

    go.drugbank.com/drugs/DB13981
    Approved

    Nomegestrol acetate, also known as NOMAC, is a progestin used in oral contraceptives, menopausal hormone therapy, and for the treatment of gynecological disorders.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  4. Drug

    Medical Cannabis

    go.drugbank.com/drugs/DB14009
    Investigational

    The use of the plant species Cannabis sativa and Cannabis indica, popularly known as marijuana, has gained popularity in recent years for the management of a wide variety of medical conditions as a wave of legalization in North America h...

    Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitors
  5. Drug

    Nabiximols

    go.drugbank.com/drugs/DB14011
    Investigational

    Nabiximols (tradename Sativex®) is a whole plant extract from the Cannabis species Cannabis sativa L. that has been purified into the active components CBD (cannabidiol) and THC (delta-9-tetrahydrocannabinol). For trademark purposes, pur...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  6. Drug

    Fosnetupitant

    go.drugbank.com/drugs/DB14019
    ApprovedInvestigational

    In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alte...

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 Substrates
  7. Drug

    Nepidermin

    go.drugbank.com/drugs/DB14145
    Investigational

    Products: HEBERPROT-P, HEBERPROT-P 75 MCG ENJEKSIYON ICIN LIYOFILIZE TOZ ICEREN FLAKON, 1 ADET
  8. Drug

    Nepicastat

    go.drugbank.com/drugs/DB12979
    Investigational

    Nepicastat has been investigated for the treatment of Cocaine Dependence and Posttraumatic Stress Disorder.

    Categories: P-glycoprotein substrates
  9. Drug

    Mephedrone

    go.drugbank.com/drugs/DB13108
    Investigational

    Mephedrone has been investigated in Alcohol-Related Disorders and Amphetamine-Related Disorders.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  10. Drug

    Lusutrombopag

    go.drugbank.com/drugs/DB13125
    ApprovedInvestigational

    Lusutrombopag is an orally bioavailable thrombopoietin receptor (TPOR) agonist developed by Shionogi & Company (Osaka, Japan). TPOR is a regulatory target site for endogenous thrombopoietin, which acts as a primary cytokine to promot...

    Categories: P-glycoprotein substrates